New York, March 25 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their BUY rating on the shares of Anacor Pharmaceuticals, Inc (NASDAQ: ANAC). The 12-month target price is set to $11.
In a research note published on March 22, the analysts mention that for the treatment of mild-to-moderate atopic dermatitis (AD), constructive information from the third Ph 2 trial for AN2728 has been posted by the company
In addition to this, AN2728 showed clear dose-dependent reaction in ADSI (atopic dermatitis severity index) scores from baseline in a dose-ranging study (number 204) in teenagers (n=86, 12 to 17 years old) over a 4 week period.
Specially, in this bilateral trial, with 62 percent of lesions in this treatment group arriving at entire or partial clearance – the most considerable enhancement of the four study arms – lesions treated with AN2728 cream 2 percent twice-daily (BID) attained an improvement of 71 percent from baseline atopic dermatitis severity index, the analysts add further.
Latest News By The Reporter
Deutsche Bank Securities Reiterates BUY Rating on Anacor Pharmaceuticals Inc (NASDAQ: ANAC) – March 25, 2013
New York, March 25 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their BUY rating on the shares of Anacor Pharmaceuticals, Inc (NASDAQ: ANAC). The 12-month target…
Deutsche Bank Securities Reports on US Daily Economic Notes – March 24, 2013
New York, March 25 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities report on US Daily Economic Notes.
In a research note published on March 22, the analysts mention that additional…
Deutsche Bank Securities Reiterates BUY Rating on General Mills (NYSE: GIS), Target Price Raised – March 21, 2013
New York, March 22 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their BUY rating on the shares of General Mills, Inc (NYSE: GIS). The 12-month target price has been raised to some…
Asian Shares Inch Higher; Dollar Stables – March 21, 2013
New York, March 21 (FinanceEnquiry.com) – Since a lift in Chinese factory action and a vow by the US Federal Reserve to its aggressive stimulus attitude pacified sentiment put off by arguing over a…
Deutsche Bank Securities Reiterates BUY Rating on ServiceNow (NYSE: NOW) – March 20, 2013
New York, March 20 (FinanceEnquiry.com) – Analyst Tom Ernst Jr at Deutsche Bank Securities reiterates BUY rating on the shares of ServiceNow, Inc (NYSE: NOW). The 12-month target price is set to…
Deutsche Bank Securities Reiterates HOLD Rating on Capital Product Partners LP (NASDAQ: CPLP) – March 19, 2013
New York, March 19 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their HOLD rating on the shares of Capital Product Partners LP (NASDAQ: CPLP). The 12-month target price…
Deutsche Bank Securities Reiterates BUY Rating on Carnival Corporation (NYSE: CCL), Target Price Reduced – March 18, 2013
New York, March 19 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their BUY rating on the shares of Carnival Corporation (NYSE: CCL). The 12-month target price has been…
Japan’s Nikkei Share Average Skids – March 18, 2013
New York, March 18 (FinanceEnquiry.com) – Reinforcing the yen and upsetting economy-sensitive shares that have increased in recent times, Nikkei share average of Japan skidded 2.7 percent on the first…
Deutsche Bank Securities Reiterates BUY Rating on Anacor Pharmaceuticals Inc (NASDAQ: ANAC) – March 18, 2013
New York, March 18 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their BUY rating on the shares of Anacor Pharmaceuticals Inc (NASDAQ: ANAC). The 12-month target price…
Deutsche Bank Securities Reiterates HOLD Rating on Kronos Worldwide (NYSE: KRO), Target Price Raised – March 13, 2013
New York, March 14 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their HOLD rating on the shares of Kronos Worldwide Inc (NYSE: KRO). The 12-month target price has been raised to some…
